1912399-75-7
1912399-75-7
Chemical Structure
Omilancor
Synonym(s): BT-11
- CAS No.: 1912399-75-7
- Formula:C30H24N8O2
- Molecular Weight:528.56
IUPAC Name: piperazine-1,4-diylbis((6-(1H-benzo[d]imidazol-2-yl)pyridin-2-yl)methanone)
InChIKey: MVHWZNBAQIGPOQ-UHFFFAOYSA-N
SMILES: O=C(N1CCN(C(C2=NC(C3=NC4=CC=CC=C4N3)=CC=C2)=O)CC1)C5=NC(C6=NC7=CC=CC=C7N6)=CC=C5
Biological Activity: Omilancor (BT-11) is an orally active lanthionine synthetase cyclase-like receptor 2 (LANCL2) activator. Omilancor can be used for the study of psoriasis, inflammatory bowel disease (IBD), and Crohn's disease (CD)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Omilancor | 98.28% | Omilancor (BT-11) is an orally active lanthionine synthetase cyclase-like receptor 2 (LANCL2) activator. Omilancor can be used for the study of psoriasis, inflammatory bowel disease (IBD), and Crohn's disease (CD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Omilancor (Standard) | ≥98% | Omilancor (Standard) is the analytical standard of Omilancor. This product is intended for research and analytical applications. BT-11 is an orally available LANCL2 binding compound for treating inflammatory bowel disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Carbo A, et al. An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. J Med Chem. 2016 Nov 23;59(22):10113-10126. [Content Brief]
- [2]. Bissel P, et al. Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. Int J Toxicol. 2016 Sep;35(5):521-9. [Content Brief]
- [3]. Tubau-Juni N, et al. First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis. Sci Rep. 2021 Oct 6;11(1):19827. [Content Brief]
